Temozolomide, DNA alkylating/methylating chemotherapeutic agent (ab141055)
Key features and details
- DNA alkylating/methylating chemotherapeutic agent
- CAS Number: 85622-93-1
- Purity: > 99%
- Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Temozolomide, DNA alkylating/methylating chemotherapeutic agent -
Description
DNA alkylating/methylating chemotherapeutic agent -
Biological description
DNA alkylating/methylating chemotherapeutic agent. Inhibits DNA replication. Anti-cancer and apoptotic activity in vitro and in vivo. Crosses the blood-brain barrier.
-
Purity
> 99% -
CAS Number
85622-93-1 -
Chemical structure
Properties
-
Chemical name
3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide -
Molecular weight
194.15 -
Molecular formula
C6H6N6O2 -
PubChem identifier
5394 -
Storage instructions
Store at +4°C. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
CN1C(=O)N2C=NC(=C2N=N1)C(=O)N -
Source
Synthetic
-
Research areas
Images
-
Chemical Structure - Temozolomide, DNA alkylating/methylating chemotherapeutic agent (ab141055)2D chemical structure image of ab141055, Temozolomide, DNA alkylating/methylating chemotherapeutic agent
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (1)
ab141055 has been referenced in 1 publication.
- Yu J et al. SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy. Bioengineered 13:14125-14137 (2022). PubMed: 35730472